Good morning :)
Switch to
Place Order

Biocon Ltd

BIOCON
Health CareBiotechnology
MidcapWith a market cap of ₹38,875 cr, stock is ranked 132
Low RiskStock is 1.88x as volatile as Nifty
323.8021.15 (-6.13%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CareBiotechnology
MidcapWith a market cap of ₹38,875 cr, stock is ranked 132
Low RiskStock is 1.88x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
52.50
PB RatioPB Ratio
4.57
Dividend YieldDiv. Yield
Sector PESector PE
38.41
Sector PBSector PB
5.12
Sector Div YldSctr Div Yld
0.68%

Forecast & RatingsDetailed Forecast 

50%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Biocon Limited is a biopharmaceutical company engaged in the research & development and manufacture of pharmaceuticals, medicinal chemical and botanical products.

Brands

Biocon

Biotech company

Investor PresentationView older 

Sep 21, 2021

PDF
View Older Presentations

Brands

Biocon

Biotech company

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Financial TrendFinancial statements 

20182019202020214.355.856.537.370.370.910.750.74
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Change in Director(s) 
Announced OnOct 21, 2021

Biocon Limited has informed the Exchange regarding Change in Director(s) of the company. | Download

Biocon Limited has informed the Exchange regarding Change in Director(s) of the company. | Download

Press Release 
Announced OnOct 21, 2021

Biocon Limited has informed the Exchange regarding a press release dated October 21, 2021, titled "Biocon Q2FY22 Revenue up 10% at Rs 1,945 Cr; EBITDA up 35% at Rs 551 Cr; Net Profit (before exceptional items) up 11% at Rs 188 Cr.". | Download

Biocon Limited has informed the Exchange regarding a press release dated October 21, 2021, titled "Biocon Q2FY22 Revenue up 10% at Rs 1,945 Cr; EBITDA up 35% at Rs 551 Cr; Net Profit (before exceptional items) up 11% at Rs 188 Cr.". | Download

Cash Dividend 
Ex. DateJul 18, 2019

Final • Div/Share: ₹ 0.5

See all events